Literature DB >> 9857185

A function-structure model for NGF-activated TRK.

M E Cunningham1, L A Greene.   

Abstract

Mechanisms regulating transit of receptor tyrosine kinases (RTKs) from inactive to active states are incompletely described, but require autophosphorylation of tyrosine(s) within a kinase domain 'activation loop'. Here, we employ functional biological assays with mutated TRK receptors to assess a 'switch' model for RTK activation. In this model: (i) ligand binding stimulates activation loop tyrosine phosphorylation; (ii) these phosphotyrosines form specific charge pairs with nearby basic residues; and (iii) the charge pairs stabilize a functionally active conformation in which the activation loop is restrained from blocking access to the kinase catalytic core. Our findings both support this model and identify residues that form specific charge pairs with each of the three TRK activation loop phosphotyrosines.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9857185      PMCID: PMC1171074          DOI: 10.1093/emboj/17.24.7282

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  46 in total

1.  NGF and other growth factors induce an association between ERK1 and the NGF receptor, gp140prototrk.

Authors:  D M Loeb; H Tsao; M H Cobb; L A Greene
Journal:  Neuron       Date:  1992-12       Impact factor: 17.173

2.  The trk tyrosine protein kinase mediates the mitogenic properties of nerve growth factor and neurotrophin-3.

Authors:  C Cordon-Cardo; P Tapley; S Q Jing; V Nanduri; E O'Rourke; F Lamballe; K Kovary; R Klein; K R Jones; L F Reichardt
Journal:  Cell       Date:  1991-07-12       Impact factor: 41.582

3.  Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons.

Authors:  A Nicholls; K A Sharp; B Honig
Journal:  Proteins       Date:  1991

4.  A cascade of tyrosine autophosphorylation in the beta-subunit activates the phosphotransferase of the insulin receptor.

Authors:  M F White; S E Shoelson; H Keutmann; C R Kahn
Journal:  J Biol Chem       Date:  1988-02-25       Impact factor: 5.157

Review 5.  Active and inactive protein kinases: structural basis for regulation.

Authors:  L N Johnson; M E Noble; D J Owen
Journal:  Cell       Date:  1996-04-19       Impact factor: 41.582

6.  Germline mutation of the RET proto-oncogene in children with total intestinal aganglionosis.

Authors:  T Shimotake; N Iwai; K Inoue; T Kimura; D Ichikawa; T Abe; J Inazawa
Journal:  J Pediatr Surg       Date:  1997-03       Impact factor: 2.545

7.  Differential utilization of Trk autophosphorylation sites.

Authors:  R A Segal; A Bhattacharyya; L A Rua; J A Alberta; R M Stephens; D R Kaplan; C D Stiles
Journal:  J Biol Chem       Date:  1996-08-16       Impact factor: 5.157

8.  Crystal structure of the tyrosine kinase domain of the human insulin receptor.

Authors:  S R Hubbard; L Wei; L Ellis; W A Hendrickson
Journal:  Nature       Date:  1994 Dec 22-29       Impact factor: 49.962

9.  Substitution of glutamine for arginine 1131. A newly identified mutation in the catalytic loop of the tyrosine kinase domain of the human insulin receptor.

Authors:  M Kishimoto; M Hashiramoto; K Yonezawa; K Shii; T Kazumi; M Kasuga
Journal:  J Biol Chem       Date:  1994-04-15       Impact factor: 5.157

10.  Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret.

Authors:  A Schuchardt; V D'Agati; L Larsson-Blomberg; F Costantini; V Pachnis
Journal:  Nature       Date:  1994-01-27       Impact factor: 49.962

View more
  20 in total

Review 1.  Neurotrophic factors and their receptors in axonal regeneration and functional recovery after peripheral nerve injury.

Authors:  J Gordon Boyd; Tessa Gordon
Journal:  Mol Neurobiol       Date:  2003-06       Impact factor: 5.590

Review 2.  Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.

Authors:  Elliott J Mufson; Scott E Counts; Sylvia E Perez; Stephen D Ginsberg
Journal:  Expert Rev Neurother       Date:  2008-11       Impact factor: 4.618

3.  Identification of critical residues within the conserved and specificity patches of nerve growth factor leading to survival or differentiation.

Authors:  Sidharth Mahapatra; Hrishikesh Mehta; Sang B Woo; Kenneth E Neet
Journal:  J Biol Chem       Date:  2009-09-17       Impact factor: 5.157

4.  Pharmacologically diverse antidepressants facilitate TRKB receptor activation by disrupting its interaction with the endocytic adaptor complex AP-2.

Authors:  Senem Merve Fred; Liina Laukkanen; Cecilia A Brunello; Liisa Vesa; Helka Göös; Iseline Cardon; Rafael Moliner; Tanja Maritzen; Markku Varjosalo; Plinio C Casarotto; Eero Castrén
Journal:  J Biol Chem       Date:  2019-10-20       Impact factor: 5.157

5.  Effects of TrkA inhibitory peptide on cancer-induced pain in a mouse melanoma model.

Authors:  Mari Tabata; Eri Murata; Koyo Ueda; Nahoko Kato-Kogoe; Yoshihiro Kuroda; Munetaka Hirose
Journal:  J Anesth       Date:  2012-05-22       Impact factor: 2.078

6.  Brain-derived neurotrophic factor but not vesicular zinc promotes TrkB activation within mossy fibers of mouse hippocampus in vivo.

Authors:  Jeffrey Helgager; Yang Zhong Huang; James O Mcnamara
Journal:  J Comp Neurol       Date:  2014-08-25       Impact factor: 3.215

7.  Deoxygedunin, a natural product with potent neurotrophic activity in mice.

Authors:  Sung-Wuk Jang; Xia Liu; Chi Bun Chan; Stefan A France; Iqbal Sayeed; Wenxue Tang; Xi Lin; Ge Xiao; Raul Andero; Qiang Chang; Kerry J Ressler; Keqiang Ye
Journal:  PLoS One       Date:  2010-07-13       Impact factor: 3.240

8.  The carboxyl terminus controls ligand-dependent activation of VEGFR-2 and its signaling.

Authors:  Rosana D Meyer; Amrik J Singh; Nader Rahimi
Journal:  J Biol Chem       Date:  2003-10-21       Impact factor: 5.157

Review 9.  The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers.

Authors:  David S Shulman; Steven G DuBois
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

Review 10.  NTRK fusion-positive cancers and TRK inhibitor therapy.

Authors:  Emiliano Cocco; Maurizio Scaltriti; Alexander Drilon
Journal:  Nat Rev Clin Oncol       Date:  2018-12       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.